Breaking News
March 18, 2019 - Taking painkillers during pregnancy is not responsible for asthma risk in children, study shows
March 18, 2019 - Prediagnosis Psychiatric Care Linked to Worse Cancer Mortality
March 18, 2019 - Paris hospital halts stool study after donor deluge
March 18, 2019 - Partial oral antibiotic therapy shows efficacy and safety in patients with infectious endocarditis
March 18, 2019 - Olympus improves access to science education through BioBus collaboration
March 18, 2019 - Depression screening does not improve quality of life in heart attack patients
March 18, 2019 - Echocardiography may aid in patient selection for TMVR
March 18, 2019 - Are ‘Inactive’ Ingredients in Your Drugs Really So Harmless?
March 18, 2019 - Scientists tackle rare retinal disease in unique research project
March 18, 2019 - Death By A Thousand Clicks
March 18, 2019 - Absorbable, antibiotic-eluting envelope can reduce rate of cardiac device infections
March 18, 2019 - Hormonal treatment associated with depression in men with prostate cancer
March 18, 2019 - Porvair Sciences launches reinforced 96-well deep round microplate
March 18, 2019 - Simplified catheter ablation could slash waiting lists for atrial fibrillation patients
March 18, 2019 - BFR therapy as part of rehabilitation following ACL surgery may slow bone loss
March 18, 2019 - A human model to test implants for cataract surgery
March 18, 2019 - New risk adjustment model could reduce financial penalty for safety net hospitals
March 18, 2019 - NHS cancer patients’ wait to start treatment worrying
March 18, 2019 - Inventiva Announces Results from Phase IIb Clinical Trial with Lanifibranor in Systemic Sclerosis
March 18, 2019 - Cologuard
March 18, 2019 - Researchers find evidence of prenatal environment tuning genomic imprinting
March 18, 2019 - Dolomite Bio launches novel Nadia product family for single-cell research
March 18, 2019 - Intellipharmaceutics Announces Resubmission of New Drug Application to the U.S. FDA for its Oxycodone ER
March 18, 2019 - Excessive gestational weight gain tied to maternal morbidity
March 18, 2019 - RCEM issues position statement on metrics to supplement four-hour standard target
March 17, 2019 - Noncontrast Brain MRI Effective for Monitoring Multiple Sclerosis
March 17, 2019 - Brain region plays key role in regulation of parenting behavior, study finds
March 17, 2019 - Natural speed limit on DNA replication sets pace for life’s first steps
March 17, 2019 - New research reveals overlooked impact of herbicide glyphosate on the environment
March 17, 2019 - Molecular patterns could help predict relapse risk in breast cancer patients
March 17, 2019 - Study confirms sensitivity of microbiological cultures for detecting cholera
March 17, 2019 - Scientists Spot Clues to Predicting Breast Cancer’s Return
March 17, 2019 - Scientists identify gene that keeps PTSD-like behavior at bay in female mice
March 17, 2019 - New method would allow doctors to detect earliest stages of cancers in the lymph nodes
March 17, 2019 - Cholesterol protein discovery raises hope for smarter drugs
March 17, 2019 - New insect medium delivers high viable cell density growth and protein yield
March 17, 2019 - Opioid crisis brings concerns about heart dangers
March 17, 2019 - Resistance Training May Prevent Type 2 Diabetes Progression
March 17, 2019 - Bioluminescence sensors make new approaches to drug discovery possible
March 17, 2019 - New FDA Rules Aim to Keep Kids From Flavored E-Cigarettes
March 17, 2019 - Vitamin B3 analogue boosts production of blood cells
March 17, 2019 - Government cuts to stop smoking services have detrimental impact on public health
March 17, 2019 - Common tool to assess potential adoptive parents lags behind societal changes
March 17, 2019 - Patients’ own cells could be the key to treating Crohn’s disease
March 17, 2019 - Diagnostic delays common in inflammatory bowel disease
March 17, 2019 - Study uncovers dramatic differences in the brains of Hispanics with dementia
March 17, 2019 - Study describes epigenetic loss that changes how cells obtain energy from cancer
March 16, 2019 - Active Bathing in Non-ICU Setting Does Not Cut Infections
March 16, 2019 - How the immune system maintains a healthy gut microbiota
March 16, 2019 - Bacteria ‘trap’ could help in the fight against antimicrobial resistance
March 16, 2019 - Hospital work environment associated with all EHR usability outcomes
March 16, 2019 - Study unravels mystery behind how the brain encodes time when forming long-term memories
March 16, 2019 - Light physical activity may lower risk of cardiovascular disease in older women
March 16, 2019 - USP15 enzyme could potentially lead to new treatments for breast, pancreatic cancer
March 16, 2019 - After Chinese Infant Gene-Editing Scandal, U.S. Health Officials Join Call for a Ban
March 16, 2019 - PACS1 syndrome – Genetics Home Reference
March 16, 2019 - Researchers discover an unexpected organization of antimicrobial molecules that amplifies immune response
March 16, 2019 - With New Study, Era of Open-Heart Surgery for Aortic Stenosis May be Ending
March 16, 2019 - Dolomite Bio introduces high throughput sNuc-Seq protocol for its Nadia Instrument
March 16, 2019 - New course prepares materials scientists for biomedical testing
March 16, 2019 - Finding clues to a functional HIV cure
March 16, 2019 - People with chronic periodontitis have higher risk for dementia
March 16, 2019 - Few heart care recommendations are based on rigorous study
March 16, 2019 - Colorectal cancer diagnosed at early age is distinct from that in older patients
March 16, 2019 - Researchers use MRI and AI techniques at birth to predict cognitive development at age 2
March 16, 2019 - Discarding information from the brain linked to more mental effort, finds study
March 16, 2019 - OTA International supplement provides current snapshot and forward look at global trauma systems
March 16, 2019 - NIH trial to track outcomes of liver transplantation from HIV+ donors to HIV+ recipients
March 16, 2019 - Apple Heart Study shows how wearable technology can help detect heart problem
March 16, 2019 - Researchers determine factors that cause stress development in the human body
March 16, 2019 - Elderly Men Undertreated for Osteoporosis
March 16, 2019 - People with chronic pain are coping with the help of Pinterest, new study reveals
March 16, 2019 - New study could reveal the complex interaction between languages and human beings who use them
March 16, 2019 - Tufts engineers develop new tool to identify metabolic signatures linked to disease
March 16, 2019 - New proteomics-based test could aid in early detection of ovarian cancer
March 16, 2019 - New research opens possibility of using sperm taken from testicles to overcome infertility
March 16, 2019 - Scientists find new proof that narcolepsy is an autoimmune disease
March 16, 2019 - FDA OKs a New Generic of the Blood Pressure Drug Valsartan to Ease Shortage Due to Recalls
March 16, 2019 - Eliminating smoking and obesity could affect racial health disparities
March 16, 2019 - Wearable tracking device achieves higher accuracy in position tracking using thermal sensors
WHO revise treatment guidelines of lymphatic filariasis due to CWRU-led study

WHO revise treatment guidelines of lymphatic filariasis due to CWRU-led study

image_pdfDownload PDFimage_print

Researchers from Case Western Reserve University School of Medicine have shown that a single “cocktail” of three pill-based anti-parasite medications is significantly more effective at killing microscopic larval worms in people diagnosed with lymphatic filariasis, commonly known as elephantiasis, than other standard two-drug combinations previously used in the global effort to eliminate this infectious disease. A combination of all three drugs given simultaneously had never been tested until now. An estimated 120 million people in over 50 tropical and subtropical countries are infected with lymphatic filariasis and another 856 million people are at risk.

As a result of these findings, published in today’s issue of the New England Journal of Medicine, the World Health Organization has revised its treatment guidelines for preventive chemotherapy of lymphatic filariasis in numerous countries worldwide where current mass treatment regimens have been unsuccessful in achieving elimination or have not yet been started. Countries that plan mass drug treatment with this new regimen include Papua New Guinea (where the study was conducted), Haiti, Indonesia, Fiji, India, Samoa, Madagascar, Kenya, São Tomé and Príncipe, Zimbabwe, and Guyana.

The disease is characterized by grossly enlarged limbs and breast (elephantiasis) and massive swelling of the scrotum (hydrocele). Of those infected, an estimated 25 million men suffer from hydrocele and 15 million, mostly women, exhibit elephantiasis of the limbs and breast.

“Lymphatic filariasis has been targeted for global elimination by the WHO in arguably the largest mass drug administration program ever attempted for an infectious disease,” said the study’s lead author, Christopher L. King, MD, PhD, professor of international health, medicine, and pathology at Case Western Reserve University School of Medicine. “Our findings offer the promise of effectively banishing this disease from a long list of health threats facing people in many developing countries.” In 2000 the World Health Organization targeted lymphatic filariasis for global elimination by 2020.

Although strides have been made with the existing two drug regimens–a 32 percent reduction in the number people at risk for lymphatic filariasis globally has been achieved to date–countries with weaker health infrastructures have struggled with the requirement to deliver at least five annual rounds of mass drug treatment at a population coverage of 65 percent in order to achieve elimination. This new drug regimen promises to require fewer rounds of annual treatment because of its greater efficacy and, therefore, increases the potential of achieving global elimination. However, even with better drug regimens, elimination cannot be achieved if people living in areas where lymphatic filariasis is endemic fail to take the drugs. An important aspect of the elimination program going forward will be to assure better coverage at the population level.

Ivermectin (IVM), diethylcarbamazine (DEC), and albendazole (ALB) are all established anti-parasite medications. In the study of 182 participants conducted in Papua New Guinea, the researchers found that a single dose of a three-drug regimen of IVM, DEC and ALB resulted in a far greater sustained clearance of microscopic worms than a single dose of a two-drug regimen of DEC and ALB. The three-drug, single dose was as effective as the two-drug regimen administered once a year for three years. This finding is especially noteworthy because public health programs find it challenging to ensure people living in filariasis endemic areas take anti-parasitic drugs annually over five or more years.

“Lymphatic filariasis is a leading cause of permanent disability worldwide,” said the study’s senior author, James W. Kazura, MD, Distinguished University Professor and director of the Center for Global Health and Diseases at Case Western Reserve University School of Medicine. “In addition to its devastating physical ramifications, which often make it challenging to work and conduct normal daily activities, the gross disfiguration can have psychosocial consequences, such as being shunned by their communities.”

Lymphatic filariasis is a round worm infection related to the dog heart worm where adult male and female worms localize in the human body’s lymphatic system. The female worms release microscopic larvae (microfilaria) that circulate in the blood and which can be ingested by mosquitoes. Mosquitoes can then allow the development of infective larvae that can be transmitted to new hosts during the blood feeding. The larvae grow into adult threadlike worms that obstruct the human lymph system, causing major fluid retention and swelling in the arms, legs, breasts, and scrotum.

To date, 6.7 billion two-drug treatments have been administered to more than 850 million people in 66 countries at least once. For more than three decades, the pharmaceutical companies Merck Inc. and GlaxoSmithKline have donated the medications used to eradicate lymphatic filariasis. More recently Eisai Co. Ltd. in Japan has donated DEC.

Tagged with:

About author

Related Articles